Skip to content

Arbutus Biopharma Corp: financial reference

Explore Arbutus Biopharma Corp financial histories from SEC filings, with original units, reporting periods, filing dates and downloadable source data.

Reported financial histories

Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.

Latest periods by selected concept and original unit
MeasurePeriod startPeriod endValueUnitFiled
Total assetsAt date2013-12-3171,715,810CAD2014-03-28
Total assetsAt date2025-12-3194,618,000USD2026-03-23
Total liabilitiesAt date2013-12-3112,522,489CAD2014-03-28
Total liabilitiesAt date2025-12-3118,042,000USD2026-03-23
Stockholders equityAt date2013-12-3159,193,321CAD2014-03-28
Stockholders equityAt date2025-12-3176,576,000USD2026-03-23
Cash and cash equivalentsAt date2013-12-3168,716,531CAD2014-03-28
Cash and cash equivalentsAt date2025-12-3118,008,000USD2026-03-23
Net income or loss2012-01-012012-12-3129,793,048CAD2013-03-27
Net income or loss2025-01-012025-12-31-33,501,000USD2026-03-23
Operating cash flow2012-01-012012-12-3133,098,556CAD2013-03-27
Operating cash flow2025-01-012025-12-31-39,637,000USD2026-03-23
Capital expenditure payments2012-01-012012-12-3114,824CAD2013-03-27
Capital expenditure payments2025-01-012025-12-310USD2026-03-23
Revenue2012-01-012012-12-3114,107,478CAD2013-03-27
Revenue2025-01-012025-12-3114,083,000USD2026-03-23
Financing cash flow2012-01-012012-12-314,544,435CAD2013-03-27
Financing cash flow2025-01-012025-12-315,721,000USD2026-03-23
Investing cash flow2012-01-012012-12-31-12,334CAD2013-03-27
Investing cash flow2025-01-012025-12-3115,580,000USD2026-03-23
Retained earnings or deficitAt date2013-12-31-167,026,633CAD2014-03-28
Retained earnings or deficitAt date2025-12-31-1,380,073,000USD2026-03-23
Basic weighted-average shares2025-01-012025-12-31191,599,600shares2026-03-23
Diluted weighted-average shares2025-01-012025-12-31191,599,600shares2026-03-23
Basic earnings per share2012-01-012012-12-312.17CAD/shares2013-03-27
Basic earnings per share2025-01-012025-12-31-0.17USD/shares2026-03-23
Diluted earnings per share2012-01-012012-12-312.08CAD/shares2013-03-27
Diluted earnings per share2025-01-012025-12-31-0.17USD/shares2026-03-23
Income tax expense or benefit2025-01-012025-12-310USD2026-03-23
Net property, plant and equipmentAt date2013-12-311,373,157CAD2014-03-28
Net property, plant and equipmentAt date2025-12-3132,000USD2026-03-23
Share-based compensation expense2012-01-012012-12-31981,656CAD2013-03-27
Share-based compensation expense2025-01-012025-12-316,953,000USD2026-03-23
Operating income or loss2012-01-012012-12-31-12,924,809CAD2013-03-27
Operating income or loss2025-01-012025-12-31-38,160,000USD2026-03-23
Current assetsAt date2013-12-3170,342,653CAD2014-03-28
Current assetsAt date2025-12-3194,456,000USD2026-03-23
Interest expense2023-01-012023-12-31459,000USD2024-03-05
Current liabilitiesAt date2013-12-3112,522,489CAD2014-03-28
Current liabilitiesAt date2025-12-316,006,000USD2026-03-23
Goodwill carrying amountAt date2019-12-310USD2021-03-04
Net current accounts receivableAt date2013-12-31116,556CAD2014-03-28
Net current accounts receivableAt date2025-12-311,447,000USD2026-03-23
Operating expenses2012-01-012012-12-3127,032,287CAD2013-03-27
Operating expenses2025-01-012025-12-3152,243,000USD2026-03-23
Research and development expense2012-01-012012-12-3118,031,718CAD2013-03-27
Research and development expense2025-01-012025-12-3125,241,000USD2026-03-23

Inspect the source

Entity
Arbutus Biopharma Corp / CIK 0001447028
Captured
2026-09-20T09:04:49.017Z
SEC response SHA-256
d0c406f420689ef604e97fe778a55d59191ec33b490a85e5747539352bb315a4

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001447028.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))